Key result
Naltrexone reduces repression and increases stress-related SBP versus placebo exclusively in hypertensive males.
RCT (n=18)
Double-blind
Randomized
Answers are grounded in this paper and cite their sources.
Randomized double-blind trial reveals naltrexone reduces repression and raises stress-induced systolic blood pressure in hypertensive men, indicating endogenous opioid dysregulation in both traits.
Objective: The present study was designed to assess the role of endogenous opioids in the relationship of hypertension to repressive coping. Methods: Ten hypertensive and 8 normotensive males were given either the opioid antagonist naltrexone or placebo in a randomized, double-blind fashion over the course of four laboratory sessions. Measures of repression and disclosure were completed and blood pressure was assessed during a laboratory stressor protocol. Results: Opioid antagonism reduced repression and increased disclosure only in the hypertensive group. Also, opioid antagonism increased stress-related systolic blood pressure only in the hypertensive group. Conclusion: The results support the hypothesis that endogenous opioid dysregulation underlies both hypertension and repressive phenomena. DBP = diastolic blood pressure; SBP = systolic blood pressure; POMS = Profile of Mood States; LCC = Life Concerns Checklist; MAS = Taylor Manifest Anxiety Scale; MCSDS = Social Desirability Scale; TAS = Toronto Alexithymia Scale.
No takes yet. Share an insight, caveat, or question.
Younger et al. (2006) conducted an RCT in Hypertension (n=18). Naltrexone vs. Placebo was evaluated on Measures of repression, disclosure of emotional material, and stress-related blood pressure. Naltrexone reduced repression, increased emotional disclosure, and raised stress-related SBP compared with placebo in the 10 hypertensive males, with no effect in the 8 normotensive males.
Synapse has enriched 10 related papers. Consider them for comparative context: